Shani Breuer

Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.

Kathleen N. Moore, Antoine Angelergues, Gottfried E. Konecny et al. · Journal of Clinical Oncology · 2023 · 53 citations

Medicine, Oncology, Pharmacology +14

Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial

Toon Van Gorp, Kathleen Moore, Gottfried E. Konecny et al. · The Lancet Oncology · 2025 · 28 citations

Medicine, Oncology, Pharmacotherapy +13

Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018)

Rebecca C. Arend, Bradley J. Monk, Ronnie Shapira‐Frommer et al. · Journal of Clinical Oncology · 2023 · 23 citations · Full text

Medicine, Oncology, Pharmacology +15

TL-118—anti-angiogenic treatment in pancreatic cancer: a case report

Shani Breuer, Ofra Maimon, Liat Appelbaum et al. · Medical Oncology · 2013 · 18 citations

Medicine, Oncology, Pharmacology +11

Ev vivo organ culture as potential prioritization tool for breast cancer targeted therapy

Albert Grinshpun, Nancy Gavert, Roy Z. Granit et al. · Cancer Biology & Therapy · 2018 · 11 citations · Full text

Medicine, Cancer Biology, Oncology +17